Critical Contrast: Nephros (NEPH) & Its Rivals

Nephros (NASDAQ: NEPH) is one of 158 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Nephros to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nephros and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nephros 0 0 0 0 N/A
Nephros Competitors 1334 4232 6927 402 2.50

As a group, “Surgical & medical instruments” companies have a potential upside of 7.29%. Given Nephros’ competitors higher possible upside, analysts clearly believe Nephros has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

49.9% of Nephros shares are owned by institutional investors. Comparatively, 44.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 8.2% of Nephros shares are owned by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Nephros and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nephros -37.47% -38.52% -26.72%
Nephros Competitors -681.91% -1,382.43% -24.75%

Valuation and Earnings

This table compares Nephros and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nephros $10.33 million -$3.42 million -14.56
Nephros Competitors $1.25 billion $127.54 million -12.13

Nephros’ competitors have higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Nephros has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Nephros’ competitors have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.


Nephros competitors beat Nephros on 7 of the 10 factors compared.

Nephros Company Profile

Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with's FREE daily email newsletter.